| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | eNOS |
| Uniprot No | P29474 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 61-160aa |
| 氨基酸序列 | QPPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQ GRPSPGPPAPEQLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAAT |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于eNOS(内皮型一氧化氮合酶)重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*"Regulation of endothelial nitric oxide synthase by HSP90 and caveolin"*
**作者**：García-Cardeña G, et al.
**摘要**：研究揭示了热休克蛋白HSP90与eNOS的相互作用机制，发现HSP90通过促进eNOS活性调节一氧化氮(NO)生成，而小窝蛋白(caveolin)则抑制其活性，为eNOS的生理调控提供了分子基础。
2. **文献名称**：*"Recombinant endothelial nitric oxide synthase: expression, purification, and characterization"*
**作者**：Fulton D, et al.
**摘要**：报道了人源eNOS重组蛋白在大肠杆菌中的高效表达与纯化方法，并验证其酶活性依赖于钙调蛋白和四氢生物蝶呤(BH4)，为后续功能研究提供了可靠工具。
3. **文献名称**：*"Crystal structure of the endothelial nitric oxide synthase heme domain in complex with L-arginine"*
**作者**：Rosenberg P, et al.
**摘要**：通过解析eNOS血红素结构域与底物L-精氨酸的复合物晶体结构，阐明了eNOS催化反应的关键氨基酸残基及底物结合位点，为靶向药物设计提供了结构依据。
4. **文献名称**：*"Targeting recombinant eNOS for cardiovascular gene therapy"*
**作者**：Papapetropoulos A, et al.
**摘要**：探索了重组eNOS蛋白在心血管疾病模型中的基因治疗潜力，证明其过表达可改善内皮功能障碍并恢复NO水平，提示其在治疗中的应用前景。
以上文献涵盖了eNOS重组蛋白的调控机制、表达方法、结构解析及治疗应用，均为该领域经典或关键研究。
**Background on eNOS Recombinant Protein**
Endothelial nitric oxide synthase (eNOS) is a critical enzyme encoded by the *NOS3* gene in humans. It belongs to the nitric oxide synthase (NOS) family, which catalyzes the production of nitric oxide (NO) from L-arginine. eNOS is primarily expressed in vascular endothelial cells and plays a central role in maintaining cardiovascular homeostasis. Its activity regulates vasodilation, blood flow, and vascular remodeling by modulating NO release, a key signaling molecule with anti-inflammatory, antithrombotic, and antioxidant properties. Dysregulation of eNOS function is linked to cardiovascular diseases, including hypertension, atherosclerosis, and endothelial dysfunction.
Recombinant eNOS protein is generated through genetic engineering, typically by expressing the *NOS3* gene in heterologous systems like *E. coli*, insect cells, or mammalian cell lines. This approach allows large-scale production of purified eNOS for research and therapeutic applications. Recombinant eNOS retains enzymatic activity, enabling studies on its structure-function relationships, post-translational modifications (e.g., phosphorylation), and interactions with cofactors (e.g., tetrahydrobiopterin) or regulatory proteins like calmodulin.
Researchers use recombinant eNOS to investigate molecular mechanisms underlying NO signaling, screen for pharmacological modulators (e.g., activators or inhibitors), and develop therapies targeting endothelial dysfunction. It also aids in studying disease models where eNOS activity is compromised, such as diabetes or ischemia-reperfusion injury. Additionally, recombinant eNOS serves as a tool for protein replacement strategies or gene therapy in preclinical studies aimed at restoring vascular health.
Overall, recombinant eNOS is vital for advancing our understanding of cardiovascular biology and developing interventions to combat eNOS-related pathologies.
×
